Halozyme Announces Findings From Janssen’s Phase 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® In Light-Chain Amyloidosis Presented At European Hematology Association 25th Annual Congress
- Saturday, June 13, 2020, 7:23
- PR Newswire
- Add a comment
SAN DIEGO, June 13, 2020 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Research & Development, LLC (Janssen) presented data from its Phase III ANDROMEDA (AMY3001) study of subcutaneous (SC) daratumumab utilizing ENHANZE® in combination with…
About the Author
admin has written 21043 stories on this site.